Retinal and choroidal angiogenesis: a review of new targets

• Main Authors: Thiago Cabral, Luiz Guilherme M. Mello, Luiz H. Lima, Júlia Polido, Caio V. Regatieri, Rubens Belfort, Vinit B. Mahajan
• Format: Article
• Language: English
• Published: BMC 2017-08-01
• Series: International Journal of Retina and Vitreous
• Subjects: Age-related macular degeneration; Angiogenesis; Anti-angiogenesis; Choroidal neovascularization; Cytokine; Ocular neovascularization
• Online Access: http://link.springer.com/article/10.1186/s40942-017-0084-9

Abstract Retinal and choroidal neovascularization are a major cause of significant visual impairment, worldwide. Understanding the various factors involved in the accompanying physiopathology is vital for development of novel treatments, and most important, for preserving patient vision. The intraocular use of anti-vascular endothelial growth factor therapeutics has improved management of the retinal and choroidal neovascularization but some patients do not respond, suggesting other vascular mediators may also contribute to ocular angiogenesis. Several recent studies examined possible new targets for future anti-angiogenic therapies. Potential targets of retinal and choroidal neovascularization therapy include members of the platelet-derived growth factor family, vascular endothelial growth factor sub-family, epidermal growth factor family, fibroblast growth factor family, transforming growth factor-β superfamily (TGF-β1, activins, follistatin and bone morphogenetic proteins), angiopoietin-like family, galectins family, integrin superfamily, as well as pigment epithelium derived factor, hepatocyte growth factor, angiopoietins, endothelins, hypoxia-inducible factors, insulin-like growth factors, cytokines, matrix metalloproteinases and their inhibitors and glycosylation proteins. This review highlights current antiangiogenic therapies under development, and discusses future retinal and choroidal pro- and anti-angiogenic targets as wells as the importance of developing of new drugs.